David C. Bupp

All filings by David C. Bupp on record concern Navidea Biopharmaceuticals, Inc. In total, 63 filings cover trades dated from 15 February 2006 to 19 December 2011.

The open-market side counts 17 purchases for €101k alongside 10 sales for €2.6M. On balance, insiders were net sellers of €2.5M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 9 share grants and 14 option exercises. So far in 2011, the count stands at no purchases and 10 sales.

A typical purchase (the median) is worth €3,848.

The newest entry dates from 20 December 2011: a share grant, in Navidea Biopharmaceuticals, Inc. The last insider purchase was made public on 16 November 2010, 5,836 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.